P-08 Borderline true hyperthermia (BTH) plus additional L-PAM bolus in the isolated perfusion for stage III lower limb melanoma. Our experience with 93 ILP

Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: The experience of the Tuscan Reference Centre

“…In our institution, over the years, progresses in technologies and methodology have improved the results with regard to side-effects through the carrying out of safer and more acceptable procedures in spite of the use of the borderline true hyperthermia. In addition, previous clinical results reported in our pilot study [ 34 ] demonstrated that borderline hyperthermia with an increase of L-PAM concentration in the advanced lower limb melanoma (stage III) has improved the locoregional disease-free interval and the overall survival rate.…”

Results of isolated lower limb perfusion for loco‐regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases

“…Between March 1990 and December 2008, 120 BTH‐ILPs for lower limb melanoma were performed with a standard dose of 10 mg/L limb volume of melphalan with or without D ‐actinomicin ( D ‐act) plus an additional bolus of 5 mg/L of L ‐PAM (2M‐BTH protocol). A preliminary pilot study we carried out verified that our BTH‐ILP procedure would be accompanied by unacceptable toxicity 10.…”